-+ 0.00%
-+ 0.00%
-+ 0.00%
Hehuang Pharmaceutical (00013) announced that Silvec® (solepinib) has been approved by the China National Drug Administration for the treatment of primary immune thrombocytopenia and warm-antibody autoimmune hemolytic anemia
Share
Listen to the news

Zhitong Finance App News, Hehuang Pharmaceutical (00013) announced that two new drug marketing applications for the novel, highly selective oral spleen tyrosine kinase (Syk) inhibitor SYVIK® (SYVIK®, solepinib/sovleplenib) were simultaneously approved by the China Drug Administration:

• Immune Thrombocytopenia: Used to treat adult patients with chronic primary immune thrombocytopenia (ITP) who have not responded well to at least one treatment in the past.

• Warm antibody autoimmune hemolytic anemia: Used to treat adult patients with warm antibody autoimmune hemolytic anemia (waIHa) who have not responded well to at least glucocorticoid therapy in the past.

The approval of an indication for immune thrombocytopenia is supported by data from the ESLIM-01 study. The ESLIM-01 study is a randomized, double-blind, placebo-controlled phase III clinical trial (NCT05029635) of 188 adult primary immune thrombocytopenia patients in China who have received at least first-line standard treatment. The results of the ESLIM-01 study were published in “The Lancet Haematology (The Lancet Haematology)”. Syveco ® showed a clinically significant rapid and long-lasting sustained platelet count response in patients with primary immune thrombocytopenia. The sustained response rate was 48.4%, while the placebo group was zero (p <0.0001). The overall response rate (ORR) for the Syveco ® group was 68.3% at weeks 0-12 and 70.6% for weeks 0-24, while the overall response rate for the placebo group was 14.5% and 16.1% (p <0.0001), respectively. Syveco ® has shown tolerable safety characteristics and improved patients' quality of life.

The approval of warm-antibody autoimmune hemolytic anemia is supported by data from the ESLIM-02 study. The ESLIM-02 study is a randomized, double-blind, placebo-controlled phase II/III clinical trial (NCT05535933) in adult patients with primary or secondary warm-antibody autoimmune hemolytic anemia who have relapsed or are refractory after previous glucocorticoid treatment. The results of phase II of the study were published in “The Lancet Haematology (The Lancet Haematology)”. The results of phase III of the study were presented at the 2026 European Society of Hematology (EHA) Annual Meeting. During weeks 5 to 24, the sustained response rate of the Syveco ® group was significantly higher than that of the placebo group (66% vs. 15%, p<0.0001). During the 24-week double-blind treatment period, Syveco ® showed better efficacy on several key indicators; specifically, the overall response rate (defined as hemoglobin (Hb) ≥100 g/L and above baseline, not receiving emergency treatment) increased significantly (70% vs. 22%, p<0.0001). Syveco® has shown good safety, and there have been no reports of treatment-related deaths or treatment interruptions.

Mr. Zheng Zefeng, Acting CEO and Chief Financial Officer of Hewang Pharmaceutical, said, “Syveco® was approved for both immunological thrombocytopenia and warm-antibody autoimmune hemolytic anemia. This is an important milestone for Hewang Pharmaceutical and marks the official approval of our first self-developed autoimmune disease drug into the commercialization stage. Patients with such chronic autoimmune hematologic diseases often face relapse and tolerability challenges due to long-term standard treatment. In key ESLIM-01 and ESLIM-02 studies, Syveco® showed clinically significant curative effects, rapid and long-lasting response, and good safety characteristics. We are committed to bringing this innovative targeted treatment option to patients across the country to fill urgent and unmet medical needs and help patients better cope with these difficult conditions.”

In addition to being approved in China, solepinib was also certified as an orphan drug by the US Food and Drug Administration (FDA) in October 2026 to treat primary immune thrombocytopenia and autoimmune hemolytic anemia. These findings highlight the clinical value of solepinib and its potential to address significant unmet medical needs worldwide. Chi-Med currently reserves all rights to solepinib globally and will continue to evaluate various strategic paths to support its global development.



Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending